Delving into the Latest Updates on Parthenolide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

NSC-157035

Target

NF-κB

Action

inhibitors

Mechanism

NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors)

Therapeutic Areas

Infectious Diseases

Active Indication

Helicobacter pylori infection

Inactive Indication

Lymphoma

Originator Organization

Ashbury Biologicals, Inc.

Active Organization

Gachon University

Inactive Organization

Ashbury Biologicals, Inc.

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC15H20O3

InChIKeyKTEXNACQROZXEV-PVLRGYAZSA-N

CAS Registry20554-84-1

This study aimed to identify prognostic TRGs using the least absolute shrinkage and selection operator (LASSO) Cox regression and multivariate Cox regression, evaluate their predictive value, explore the association between TRG scores and immune cell infiltration, and assess the sensitivity of high-scoring AML patients to chemotherapeutic agents.

Method::

Univariate Cox regression analysis was conducted on the TCGA cohort to identify prognostic TRGs and to develop the TRG scoring model using LASSO-Cox and multivariate Cox regression. Validation was performed on the GSE37642 cohort. Immune cell infiltration patterns were assessed through computational analysis, and the sensitivity to chemotherapeutic agents was evaluated.

Results::

Thirteen prognostic TRGs were identified, and a seven-TRG scoring model (including NOP10, OBFC1, PINX1, RPA2, SMG5, MAPKAPK5, and SMN1) was developed. Higher TRG scores were associated with a poorer prognosis, as confirmed in the GSE37642 cohort, and remained an independent prognostic factor even after adjusting for other clinical characteristics. The high-score group was characterized by elevated infiltration of B cells, T helper cells, natural killer cells, tumor-infiltrating lymphocytes, regulatory T (Treg) cells, M2 macrophages, neutrophils, and monocytes, along with reduced infiltration of gamma delta T cells, CD4- T cells, and resting mast cells. Moreover, high infiltration of M2 macrophages and Tregs was associated with poor overall survival compared to low infiltration. Notably, high-risk AML patients were resistant to Erlotinib, Parthenolide, and Nutlin-3a, but sensitive to AC220, Midostaurin, and Tipifarnib. Additionally, using RT-qPCR, we observed significantly higher expression of two model genes, OBFC1 and SMN1, in AML tissues compared to control tissues.

Conclusion::

This innovative TRG scoring model demonstrates considerable predictive value for AML patient prognosis, offering valuable insights for optimizing treatment strategies and personalized medicine approaches. The identified TRGs and associated scoring models could aid in risk stratification and guide tailored therapeutic interventions in AML patients.

01 Jan 2026·JOURNAL OF ETHNOPHARMACOLOGY

Pi Ji Pills reshape the pancreatic cancer immune microenvironment and enhance the efficacy of gemcitabine through dual mechanisms of PI3K/AKT pathway blockade and NETs inhibition

Article

Author: Li, Yi ; Liu, Fudong ; Jiang, Xiaochen ; Pang, Bo ; Shen, Qian ; Zhang, Chuanlong ; Lin, Hai

ETHNOPHARMACOLOGICAL RELEVANCE:

Pancreatic cancer presents a significant challenge in clinical treatment. Pi Ji Pills (PJP) is a compound formula made up of seven traditional Chinese medicinal herbs. It has demonstrated positive clinical outcomes in the treatment of pancreatic cancer, and its potential pharmacological mechanisms warrant further investigation.

AIM OF THE STUDY:

This study aimed to identify the possible mechanisms by which PJP inhibits pancreatic cancer, followed by experimental verification and more profound exploration.

MATERIALS AND METHODS:

An in vivo pancreatic cancer xenograft model was established to observe the effect and safety of PJP on tumor growth. The SW1990 cells were cultured to investigate the intervention effects of PJP-containing serum on the malignant biological behavior of pancreatic cancer cells. Subsequently, network pharmacology analysis was employed to explore the potential mechanisms. Furthermore, both in vivo and in vitro experiments were conducted to validate the core pathways and targets. An in-depth exploration was performed, with a focus on the role of neutrophil extracellular traps (NETs) in the inhibition of pancreatic cancer by PJP.

RESULTS:

PJP inhibits tumor growth, and its combination with gemcitabine exhibits enhanced inhibitory effects, partially alleviating immune suppression. PJP-containing serum was found to inhibit the malignant biological behavior of SW1990 cells. naringenin, atractylenolide I, isoalantolactone, curcumenol, parthenolide, and arglabin are the main active components of PJP. PJP inhibits PI3K/AKT pathway, key to its anti-pancreatic cancer effects. Additionally, PJP's treatment inhibited SW1990 cell proliferation indenpence of reducing IL-8 and downregulating NETs-related protein expression in the co-culture system.

CONCLUSIONS:

PJP combats pancreatic cancer and enhances gemcitabine efficacy by remodeling the immunosuppressive tumor microenvironment. This anticancer effect may be attributed to a dual-target mechanism involving suppression of the PI3K/AKT pathway and regulation of NETs formation in the tumor microenvironment.

01 Dec 2025·TISSUE & CELL

A combined therapeutic approach: Parthenolide and vincristine modulate autophagy in B-cell acute lymphoblastic leukemia

Article

Author: Zare, Farahnaz ; Zarei, Elmira ; Dehbidi, Gholamreza Rafiei ; Tamaddon, Gholamhossein ; Omidkhoda, Azadeh ; Nazari, Mansoureh ; Namdari, Sepide

BACKGROUND:

Parthenolide (PTL), derived from Tanacetum parthenium, is known for its anti-inflammatory and anti-cancer properties, primarily through NF-κB inhibition and modulation of reactive oxygen species. This study investigates PTL's potential as a complementary treatment for B-Cell Acute Lymphoblastic Leukemia, focusing on its effects on autophagy, apoptosis, and proliferation in the Nalm-6 cell line, alongside vincristine, with the aim of addressing challenges such as multi-drug resistance.

METHODS:

Nalm-6 cells were treated with increasing concentrations of PTL and VCR to determine their IC50 values, followed by combination treatments with sub-IC50 doses. Apoptosis was assessed using flow cytometry, while changes in autophagy-related gene expression (BECN1, ATG10, LC3, and P62) were measured via Real-time PCR, and LC3 protein levels were analyzed through Immunoblotting.

RESULTS:

The results revealed that both PTL and VCR inhibited Nalm-6 cell proliferation in a concentration and time-dependent manner, with a synergistic effect observed in combined treatments. This combination also increased apoptosis and significantly enhanced the expression of autophagy-related genes ATG10, LC3 and BECN1 while decreasing P62 expression. Additionally, VCR and PTL increased LC3B-II protein levels.

CONCLUSION:

Overall, the study indicates that combined treatment promotes autophagy and apoptosis, suggesting that PTL could be a beneficial adjunct to chemotherapy for treating B-ALL in the future.

100 Deals associated with Parthenolide

Login to view more data